{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}],"title":"Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"Objective tumor regression response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.0. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum LD. Progressive Disease (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","groups":[{"description":"1/Phase I:\n\nDrug: Fludarabine\n\nDays -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG000","title":"Arm A01 Anti-mesothelin CAR PBL 1x10^6 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG001","title":"Arm A02 Anti-mesothelin CAR PBL 3x10^6 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG002","title":"Arm A03 Anti-mesothelin CAR PBL 1x10^7 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG003","title":"Arm A04 Anti-mesothelin CAR PBL 3x10^7 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG004","title":"Arm A05 Anti-mesothelin CAR PBL 1x10^8 + IL-2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3.5 mos.","title":"Number of Patients With Objective Tumor Regression","type":"PRIMARY","unitOfMeasure":"Participants"}